drugset

drugset / Trial / NCT01082263

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

NCT01082263 ↗

Phase 1 Completed 24 enrolled Sumitomo Pharma America, Inc.

RandomizedSingle-groupOpen-label

Summary

A Phase I, Drug-Drug Interaction Study between Midazolam and Lurasidone HCl.

Timeline

Start: 2008-10
Primary completion: 2008-11
Completion: 2008-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lurasidone	Small molecule	120 mg	—
Subject	Midazolam	Small molecule	5 mg	—

Indications